Narayan Vivek, Ross Ashley E, Parikh Ravi B, Nohria Anju, Morgans Alicia K
Division of Hematology/Medical Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Urology, Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA.
JACC CardioOncol. 2021 Dec 21;3(5):737-741. doi: 10.1016/j.jaccao.2021.09.014. eCollection 2021 Dec.
• Androgen deprivation therapy is associated with metabolic derangements due to profound hypogonadism that can increase the risk of CV disease in prostate cancer survivors. • Therapeutic advances have resulted in prolonged patient exposure to androgen deprivation therapy, thereby increasing CV complications for many prostate cancer survivors. • A systematic approach to monitoring and addressing reversible CV risk factors and purposeful engagement in multidisciplinary care between oncologists, urologists, and cardiologists is critical to optimizing CV outcomes in men with prostate cancer.
• 雄激素剥夺疗法与严重性腺功能减退导致的代谢紊乱有关，这会增加前列腺癌幸存者患心血管疾病的风险。
• 治疗进展导致患者接受雄激素剥夺疗法的时间延长，从而增加了许多前列腺癌幸存者的心血管并发症。
• 采用系统方法监测和处理可逆性心血管危险因素，并让肿瘤学家、泌尿科医生和心脏病专家有目的地参与多学科护理，对于优化前列腺癌男性患者的心血管结局至关重要。
